Atomo Diagnostics Ltd. (AU:AT1) has released an update.
Atomo Diagnostics Limited, an Australian medical device provider, has reported a late submission of the Appendix 3Y due to an administrative oversight, which has since been rectified. The company reaffirms its commitment to compliance with ASX Listing Rules and views the incident as isolated, maintaining confidence in its disclosure practices. Atomo, known for its rapid diagnostic test devices across various health applications, including COVID-19 and HIV, emphasizes that current practices are sufficient for adherence to regulatory standards.
For further insights into AU:AT1 stock, check out TipRanks’ Stock Analysis page.
